




Author(s)竹内, 節夫; 柴, 忠明




Type Departmental Bulletin Paper
Textversionpublisher
Kyoto University







Studies on Thrombolytic Therapy for Venous 
Thrombosis in the Extremities 
一一Dynamicsof Plasmin Inhibitor and FDP 
Following Administration of Urokinase-
SETsuo TAKEUCHI and T ADAAKI SHIBA 
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(Director : Prof. Dr. SABURO AwAzu) 
In this study, plasmin inhibitors and plasmiminogen in thrombi were determined. 
Also, the dynamics of fibrin and fibrinogen degradation products (FDP), plasmin inhibitors, 
and plasminogen following administration of urokinase were deter mined experimentally 
and clinically. 
Sventeen cases of venous thrombosis in which the patients received only thrombolytic 
th巴rapywith urokinase were investigated. 
The following results were obtained : 
1. Plasmin inhibitors were present in thrombi. 
2. Plasmin inhibitor activity in peripheral blood decreased following administration of 
24,000 to 36,000 IU of urokinase in clinical cases. 
3. FDP in peripheral blood increased following administration of 24,000 to 36,000 IU of 
urokinase in clinical cases. 
4. In thrombolytic therapy it is important to decrease plasmin inhibitor activity and 
increase FDP. 
5. Thrombolytic therapy seems to have an effect on thrombi for only 3-4 days after their 
formation. 
Key words : Urokinase, FDP, Plasmin Inhibitor, Venous Thrombosis, Thrombolytic Therapy. 
索引語：ウロキナーゼ，フィプリン体分解産物，線溶限止因子，静脈血栓症，血栓溶解療法．
Present address : The 2nd Department of Surgery, Toho University of Medicine, Omorinish1, 




























(l) 0.5M燐酸緩衝液（PBS)(pH 7_ 4) 
(2) 0. 005M PBS加 0.85% NaCl (pH 7. 4) 
(3) 0. 005M PBS加 lMNaCl (pH 7. 4) 
(4) O. lM酪酸溶液









0. 005M PBS加 0.85%NaClで用時に溶解lし
て使用
(1) Bovine plasminogen (pig）：第一化学製
自由 Bovine plasminogen free fibrinogen (pig 
free fibg）：第一化学製
















動脈及び静脈血栓の各 lgをそれぞれ 0.005MPBS 








column K 0. 005M PBS加 0.85% NaCl 3mlを注
いで得た分画を併せて fractionIとした．次いで
0.005M PBS加 lMNaCl 3mlで溶出を行い，得た
分画を fractionI どした．次いで 0.lM酪酸 3ml
で溶出を行い，得た分画を 0.5M NaP04溶液で pH
7.4 I乙調節して fractionIIとした．
実際の測定にあたっては静脈血栓の homogenate
の supernatant, fraction I, fraction I, fraction 
III及び両血栓の homogenateに lOOOu/mlの SK
O. lml又は 500u/mlの UKO. lml を加えて pig




4.実験的 UK添加に伴う plasmininhibitor と
FDPの変動















F一0.1M CH~COOH 3 ml 
出以→面 0.5 M Na2HP ψ 
PH 7.5 
fraction .III 
Fig. 1 Separation of plasminogen and plasmin inhibitor from a thrombus by affinity chromatography 
on lysine agarose 
加した試験管内1:., 0. 2% pig free fibg 0. 4ml に
25u/ml thrombin 0. lmlを加えて調製した fibrin
clotを投入し， 38。C恒温槽中で放置し経時的1r.血清中
の plasmininhibitorを TNP10n11法で， FOPを
FOPテストで測定した．
5.臨床的 UK投与に伴う plasminogen,plasmin 
inhibitor, FDPの変動









































Table. 1 Cases of venous thrombosis in the extremities 
No. Age Sex Focus Duration Total Dosage 
l 36 f 1.femoral v. 1 day 480,000 U 
2 29 m 1. femoral v. 6 days 360, 000 u 
3 55 m 1. femoral v. 14 days 996, 000 u 
4 24 m r. femoral v. 10 days 360, 000 U 
5 71 m !.femoral v. 1 day 48,000 U 
6 47 m r.popl工tealv. 14 days 540,000 u 
7 67 f r.femoral v. 6 days 362,000 U 
8 46 m r.femoral v. 6 days 360,000 U 
9 24 m r.popliteal v. 4 days 336,000 U 
10 29 m 1. femoral v. 2 days 300, 000 U 
11 56 m r.popliteal v 5 days 720,000 U 
12 31 f 1. femoral v. 1 day 396, 000 U 
13 17 f !.femoral v. 5 days 1,080,000 U 
14 40 f !.femoral v. 4 days 336,000 U 
15 64 f 1.popliteal v. 1 day 24,000 U 
16 65 f r.popliteal v. 30 days 516,000 U 
17 42 m r.popliteal v. 4days 552,000 U 
Duration:time lapse between the onset of disease and 
the primary treatment. 
f:female m:male l:left r:right v:vein 
Table. 2 Determination of Fibrinolysis in Thrombi 




















20.x26 mm2 20x21 mm2 trace 
17xl8 mm2 17xl8 mm2 trace 
tested by fibrin plate method 
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fraction II工 2x2 rnm2 2x2 rnm2 
tested by fibrin plate method 
CU/ml x一一－x 6,000 u 
←一－inhibitor b. 6. 24 ,000 u 
40l x40 口一一一一口 36,000 u ， 














／ 10 ， 
〆
L’ 。30 60 120 180 min. 
before after 
estimated b日 TNP method 
and FDPL test 
Fig. 2 Dynamics of FDP and plasmin inhibitor 









tested by TNP method 
Fig. 3 Dynamics of plasmin inhibitors with UK 















pre 2 3 
tested by FDPL test 
4 
hour 
Fig. 4 Changes of FDP with UK administration 
(7 cases) 
Table. 4 Jnvestgation of early efficacy in 17 cases with deep venous thrombosis 
treated with UK 
Average Average 
No. Duration Total Dosage 
Effective 3.4 days 540,000 u 5/17 
Fair 6.4 days 420,000 u 7/17 
工neffectie 10.4 days 372, 000 u 5/17 
Effective:cases in which all symptoms disappeard 
and venographic findings indicated recanalization. 
Fair:cases in which all sヲmptoms disappeard but 
venographic findings did not reveal recanalization 
or the situation was uncertain due to a lack of 
venography. 
Ineffective:cases in which showed no improvement 
or became worse. 
Duration:time lapse between the onset of desease 














処理による plasmin活性の出現は血栓内に plasmin 
inhibitorが存在することを示す1つの根拠となろう．
且つ又，既でl二治家2)12)13）により述べられている如く









る さて，実験的 UK添加に伴う plasmininhibitor 
とFDPの変動の測定では plasmininhibitorの減






投与された UKの一部は末梢血中の UKinhibitor 
3)15）に阻害されることは充分に予想される．更に，未
だ UKinhibitorの作用を受ける以前の UKは衣梢
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